GSK Shares Positive Data for AREXVY, its Respiratory Syncytial Virus (RSV) Older Adult Vaccine, Indicating Protection Over Two RSV Seasons

GSK has announced positive results from its clinical trial of AREXVY, a vaccine for respiratory syncytial virus (RSV) in older adults. The AReSVi-006 phase III trial found that the vaccine provided protection against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, including in participants with underlying medical conditions. Safety and reactogenicity data were c..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 22.
  • textsms

FDA Action Alert: BMS, GSK, Ironwood, Ipsen/Albireo

The FDA has four target action dates this week, including approvals for drugs to treat functional constipation, Alagille syndrome, myelofibrosis and symptomatic obstructive hypertrophic cardiomyopathy. Ironwood Pharmaceuticals' Linzess is set to be approved as a treatment for functional constipation in children aged 6-17 years on June 14th. Albireo's Bylvay may also receive approval on June 15th..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 13.
  • textsms